Cargando…

Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?

BACKGROUND: Tumor micro-angiogenesis and lymphangiogenesis are effective prognostic predictors in many solid malignancies. However, its role on Xp11.2 translocation RCC has not been fully elucidated. Herein, we purposed to explore the correlation between quantitative parameters of tumor-related micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Wenliang, Yang, Jun, Liu, Ning, Pu, Xiaohong, Qu, Feng, Xu, Linfeng, Zhao, Xiaozhi, Li, Xiaogong, Zhang, Gutian, Guo, Hongqian, Li, Dongmei, Gan, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709278/
https://www.ncbi.nlm.nih.gov/pubmed/33267784
http://dx.doi.org/10.1186/s12885-020-07696-2
_version_ 1783617715477413888
author Ma, Wenliang
Yang, Jun
Liu, Ning
Pu, Xiaohong
Qu, Feng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
author_facet Ma, Wenliang
Yang, Jun
Liu, Ning
Pu, Xiaohong
Qu, Feng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
author_sort Ma, Wenliang
collection PubMed
description BACKGROUND: Tumor micro-angiogenesis and lymphangiogenesis are effective prognostic predictors in many solid malignancies. However, its role on Xp11.2 translocation RCC has not been fully elucidated. Herein, we purposed to explore the correlation between quantitative parameters of tumor-related micro-angiogenesis or lymphangiogenesis and the prognosis of Xp11.2 translocation renal cell carcinoma (Xp11.2 translocation RCC). METHODS: Tissue samples were obtained from 34 Xp11.2 translocation RCC and 77 clear cell renal cell carcinoma (ccRCC) between January 2007 and December 2018. Micro-angiogenesis was detected using CD34 antibody and quantified with microvessel density (MVD) and microvessel area (MVA), while the lymphangiogenesis in RCC was immunostained with D2–40 antibody and assessed using lymphatic vessel density (LVD) and lymphatic vessel area (LVA). The Kaplan-Meier method of survival analysis was used to estimate prognosis, and both univariate and multivariate analysis was performing using the Cox proportional hazards. RESULTS: The MVD and MVA of Xp11.2 translocation RCC in two detected areas (intratumoral and peritumoral area) were not significantly different from that of ccRCC (all P > 0.05). Notably, D2–40-positive lymphatic vessels of Xp11.2 translocation RCC were highly detected in the peritumoral area compared to the intratumoral area. Interestingly, the peritumoral LVD and LVA of Xp11.2 translocation RCC were higher than that of ccRCC (all P < 0.05). Furthermore, both intratumoral MVD or MVA and peritumoral LVD or LVA were significantly associated with pT stage, pN stage, cM stage, AJCC stage, and WHO/ISUP grade (all P < 0.05). Univariate analysis of Cancer-specific survival (CSS) revealed that CSS was substantially longer in patients with low intratumoral MVD or MVA than in patients with high intratumoral MVD or MVA (P = 0.005 and P = 0.001, respectively). Lastly, the Cox proportional hazards model in CSS demonstrated that both intratumoral MVD or MVA and peritumoral LVD or LVA were not independent prognostic parameters (all P > 0.05). CONCLUSIONS: This study outlines that Xp11.2 translocation RCC is a highly vascularized solid RCC, characterized by rich lymph vessels in the peritumoral area. Quantitative parameters of micro-angiogenesis and lymphangiogenesis could not be considered as novel prognostic factors for patients with xp11.2 translocation RCC.
format Online
Article
Text
id pubmed-7709278
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77092782020-12-02 Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma? Ma, Wenliang Yang, Jun Liu, Ning Pu, Xiaohong Qu, Feng Xu, Linfeng Zhao, Xiaozhi Li, Xiaogong Zhang, Gutian Guo, Hongqian Li, Dongmei Gan, Weidong BMC Cancer Research Article BACKGROUND: Tumor micro-angiogenesis and lymphangiogenesis are effective prognostic predictors in many solid malignancies. However, its role on Xp11.2 translocation RCC has not been fully elucidated. Herein, we purposed to explore the correlation between quantitative parameters of tumor-related micro-angiogenesis or lymphangiogenesis and the prognosis of Xp11.2 translocation renal cell carcinoma (Xp11.2 translocation RCC). METHODS: Tissue samples were obtained from 34 Xp11.2 translocation RCC and 77 clear cell renal cell carcinoma (ccRCC) between January 2007 and December 2018. Micro-angiogenesis was detected using CD34 antibody and quantified with microvessel density (MVD) and microvessel area (MVA), while the lymphangiogenesis in RCC was immunostained with D2–40 antibody and assessed using lymphatic vessel density (LVD) and lymphatic vessel area (LVA). The Kaplan-Meier method of survival analysis was used to estimate prognosis, and both univariate and multivariate analysis was performing using the Cox proportional hazards. RESULTS: The MVD and MVA of Xp11.2 translocation RCC in two detected areas (intratumoral and peritumoral area) were not significantly different from that of ccRCC (all P > 0.05). Notably, D2–40-positive lymphatic vessels of Xp11.2 translocation RCC were highly detected in the peritumoral area compared to the intratumoral area. Interestingly, the peritumoral LVD and LVA of Xp11.2 translocation RCC were higher than that of ccRCC (all P < 0.05). Furthermore, both intratumoral MVD or MVA and peritumoral LVD or LVA were significantly associated with pT stage, pN stage, cM stage, AJCC stage, and WHO/ISUP grade (all P < 0.05). Univariate analysis of Cancer-specific survival (CSS) revealed that CSS was substantially longer in patients with low intratumoral MVD or MVA than in patients with high intratumoral MVD or MVA (P = 0.005 and P = 0.001, respectively). Lastly, the Cox proportional hazards model in CSS demonstrated that both intratumoral MVD or MVA and peritumoral LVD or LVA were not independent prognostic parameters (all P > 0.05). CONCLUSIONS: This study outlines that Xp11.2 translocation RCC is a highly vascularized solid RCC, characterized by rich lymph vessels in the peritumoral area. Quantitative parameters of micro-angiogenesis and lymphangiogenesis could not be considered as novel prognostic factors for patients with xp11.2 translocation RCC. BioMed Central 2020-12-02 /pmc/articles/PMC7709278/ /pubmed/33267784 http://dx.doi.org/10.1186/s12885-020-07696-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ma, Wenliang
Yang, Jun
Liu, Ning
Pu, Xiaohong
Qu, Feng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title_full Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title_fullStr Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title_full_unstemmed Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title_short Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
title_sort are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with xp11.2 translocation renal cell carcinoma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709278/
https://www.ncbi.nlm.nih.gov/pubmed/33267784
http://dx.doi.org/10.1186/s12885-020-07696-2
work_keys_str_mv AT mawenliang aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT yangjun aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT liuning aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT puxiaohong aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT qufeng aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT xulinfeng aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT zhaoxiaozhi aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT lixiaogong aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT zhanggutian aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT guohongqian aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT lidongmei aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma
AT ganweidong aretumorassociatedmicroangiogenesisandlymphangiogenesisconsideredasthenovelprognosticfactorsforpatientswithxp112translocationrenalcellcarcinoma